Search results
Results from the WOW.Com Content Network
This article aims at keeping an up-to-date list of Coronavirus strains and subspecies successfully isolated and cultured in laboratory, a task which is often challenging. When relevant it shall include a few synthetic chimera as well as some strains that were only propagated in laboratory animals.
Because of AAV's specialized gene therapy advantages, researchers have created an altered version of AAV termed self-complementary adeno-associated virus (scAAV). Whereas AAV packages a single strand of DNA and must wait for its second strand to be synthesized, scAAV packages two shorter strands that are complementary to each other.
A 2021 U.S. Centers for Disease Control and Prevention poster on the COVID-19 viral vector vaccines. Viral vectors are modified viruses designed to deliver genetic material into cells. This process can be performed inside an organism or in cell culture. Viral vectors have widespread applications in basic research, agriculture, and medicine.
The National Transportation Safety Board (NTSB) is set to provide an update Saturday on the investigation into the recent aircraft collision outside of Reagan Washington National Airport. More ...
Coronavirus diseases are caused by viruses in the coronavirus subfamily, a group of related RNA viruses that cause diseases in mammals and birds. In humans and birds, the group of viruses cause respiratory tract infections that can range from mild to lethal.
The Assault Amphibious Vehicle [2] [3] (AAV)—official designation AAVP-7A1 (formerly known as Landing Vehicle, Tracked, Personnel-7 abbr. LVTP-7)—is a fully tracked amphibious landing vehicle manufactured by U.S. Combat Systems (previously by United Defense, a former division of FMC Corporation).
The Australian Open has seen its biggest shock so far as 19-year-old American qualifier Learner Tien stunned three-time finalist Daniil Medvedev in a five-set epic to reach the third round on his ...
Strasbourg, France, October 14, 2024, 7:30 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that its randomized Phase II study to evaluate TG4001 in combination with avelumab versus avelumab alone in patients with recurrent or metastatic ...